

In re Application of Topalian et al.  
 Application No. 08/533,895  
 Filed: September 26, 1995  
 For: MHC CLASS II RESTRICTED MELANOMA ANTIGENS AND THEIR USE IN THERAPEUTIC METHODS

**PATENT**  
 Attorney Docket No. 219490  
 DHHS Ref. No. E-221-95/0  
 Date: November 18, 2002

**U.S. PATENT AND TRADEMARK OFFICE**  
**Box Sequence, P.O. Box 2327**  
**Arlington, VA 22202**

**RECEIVED**

**NOV 26 2002**

Sir:

**TECH CENTER 1600/2900**

Transmitted herewith is an Amendment and Response to Office Action in the subject application.

- ☐ Applicants claim small entity status of this application under 37 CFR 1.27.
- ☒ Petition for Extension of Time
- ☒ Applicants petition for a two month extension of time under 37 CFR 1.136, the fee for which is \$ 390.00 (enclosed).
- ☐ Applicants believe that no petition for an extension of time is necessary. However, to the extent that such petition is deemed necessary, Applicants hereby petition for a sufficient extension of time to render the present submission timely. Please charge Deposit Account No. 12-1216 for the appropriate petition fee.
- ☒ No additional claim fee is required.
- ☒ Other: Amendments to the Specification and Claims Made in Response to Office Action Dated June 17, 2002; Pending Claims After Amendments Made in Response to Office Action Dated June 17, 2002; Submission of Sequence Listing and Sequence Listing (paper copy and on diskette)

The claim fee has been calculated as shown below:

					SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	EXTRA CLAIMS PRESENT	RATE	ADDIT. CLAIM FEE	RATE	ADDIT. CLAIM FEE
TOTAL	38	MINUS	63	=0	x 9=	\$	x 18=	\$0.00
INDEPENDENT	1	MINUS	4	=0	x 42=	\$	x 84=	\$0.00
<input type="checkbox"/>	FIRST PRESENTATION OF MULTIPLE CLAIM				+ 140=	\$	+ 280=	\$
					TOTAL	\$	TOTAL	\$0.00

- ☒ Please charge my Deposit Account No. 12-1216 in the amount of \$390.00. A duplicate copy of this sheet is attached.
- ☒ The Commissioner is hereby authorized to charge any deficiencies in the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1216. A duplicate copy of this sheet is attached.
- ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,


LEYDIG, VOIT & MAYER, LTD.

By

  
 Carol Larcher, Reg. No. 35,243

Leydig, Voit & Mayer, Ltd.  
 Two Prudential Plaza, Suite 4900  
 180 North Stetson  
 Chicago, Illinois 60601-6780  
 (312) 616-5600 (telephone)  
 (312) 616-5700 (facsimile)

THE PATENT AND TRADEMARK OFFICE IS RESPECTFULLY REQUESTED TO PLACE ITS STAMP ON THIS POSTAL CARD AND PLACE IT IN THE OUTGOING MAIL TO SHOW THE FOLLOWING PAPERS HAVE BEEN RECEIVED.



Attorney Docket No. 219490  
DHHS Ref. No.: E-221-95/0  
In Re Application of: Topalian et al.  
U.S. Patent Application: 08/533,895  
Filed: September 26, 1995  
For: MHC CLASS II RESTRICTED MELANOMA ANTIGENS AND THEIR USE IN  
THERAPEUTIC METHODS

Enclosed: Form PTO-1083 (1 pg in duplicate); Amendment and Response to Office Action with Certificate of Mailing (13 pgs.); Amendments to the Specifications and Claims Made in Response to Office Action Dated June 17, 2002 (6 pgs.); Pending Claims After Amendments Made in Response to Office Action dated June 17, 2002 (5 pgs.); Submission of Sequence (1pg.); Sequence Listing (17pgs.); diskette and postcard.

Mailed: November 18, 2002  
CL/kng

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900